NEWS FEATURE
02 October 2023
Two start-ups are taking a deep dive into cancer genomes to unearth new therapeutic targets.
Laura DeFrancesco
Senior Editor, Nature Biotechnology
Too many cancer therapies target the same pathways. So say the founders of two cancer-focused biotech start-ups that got their footing last year. Case in point: of the six approved chimeric antigen receptor (CAR)-T therapies, four target the same molecule (CD-19), and the other two target another blood-related antigen (BCMA). But now Cartography Biosciences and Nested Therapeutics believe they have pathways to better targets. Both companies are delving into large databases of cancer mutations to find targets in proteins or pathways that have either escaped detection or have been ignored because they are present at too low a frequency. Each company has a distinct strategy to reach their goal of finding these diamonds in the rough. Cartography board member Jorge Conde, a principal at Andreessen Horowitz, which was an early investor in the company, says, “We have a lot of really great tools in terms of therapeutics; what we have shortage of is novel targets against which we can direct those tools.”
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
doi: https://doi.org/10.1038/d41587-023-00013-9
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/d41587-023-00013-9